Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621317 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
A Phase 2 study of Immune System Diseases and Peanut Allergy, sponsored by Aravax Pty.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT05621317: Active Phase 2 study of Immune System Diseases and Peanut Allergy, sponsored by Aravax Pty.
NCT05621317 is a Phase 2 study of Immune System Diseases and Peanut Allergy that is active but no longer recruiting, run by Aravax Pty. The registered enrollment target is 90 participants, below the 148-participant average among 18 other Immune System Diseases trials with a reported enrollment target (39% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05621317, a Phase 2 study of Immune System Diseases and Peanut Allergy, is active but no longer recruiting, sponsored by Aravax Pty.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PVX-108
Study Locations (14)
Maryland
- Johns Hopkins Hospital - Baltimore
- IAA Clinical Research - Chevy Chase
New South Wales
- Sydney Children's Hospital - Randwick
- The Children's Hospital at Westmead - Westmead
Arkansas
- Arkansas Children's Research Institute - Little Rock
California
- Peninsula Research Associates - Rolling Hills Estates
Georgia
- Children's Healthcare of Atlanta - Atlanta
Indiana
- Riley Children's Hospital at IU - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT05621317 still lists
NCT05621317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 148-participant average among 18 other Immune System Diseases trials with a reported enrollment target (39% lower).
The record links to 4 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05621317 lists 14 locations in 12 states (Maryland, New South Wales, Arkansas).
Frequently Asked Questions
What is clinical trial NCT05621317 about?
NCT05621317 is a clinical study titled "A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy". The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
What is the current status of trial NCT05621317?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-02-09. Estimated completion is 2027-06.
What conditions does trial NCT05621317 study?
This clinical trial studies the following conditions: Immune System Diseases, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis.
What interventions are being tested in trial NCT05621317?
The interventions under investigation include: Placebo (BIOLOGICAL), PVX-108 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05621317?
This trial is sponsored by Aravax Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621317 being conducted?
This trial has 14 study locations across Arkansas, California, Georgia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05621317's enrollment target sits among peer trials
90 6th of 18 higher than 13 of 18 other Immune System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immune System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
ACTIVE NOT RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI